• Mashup Score: 47

    Background: Intramural site of origin is a major cause of ablation failure of ventricular arrhythmias and the optimal strategy is unclear. This study investigated the efficacy of a stepwise ablation approach for intramural outflow tract (OT) premature ventricular complexes (PVCs) guided by mapping of the septal coronary venous system. Methods: Consecutive patients with OT PVCs were included in which an intramural origin was confirmed by demonstration of earliest activation in a septal coronary vein. Radiofrequency ablation was performed from the closest endocardial site in the left (LVOT) and/or right ventricular OT (RVOT) independent of the local activation time. If there was no suppression by endocardial ablation, retrograde transvenous ethanol infusion with a single or double balloon technique was performed, targeting the earliest septal coronary vein. If venous anatomy was not suitable for ethanol ablation or if this failed, bipolar ablation was performed. Results: Sixty patients (

    Tweet Tweets with this article
    • #CircatHRS25 A stepwise ablation strategy for intramural outflow tract (OT) premature ventricular complexes (PVCs) guided by mapping of the septal coronary veins is highly successful for intramural OT PVCs. https://t.co/cOPyfgUHUw https://t.co/mvbIVWHIzF

  • Mashup Score: 26

    Background: The PRAETORIAN trial investigated the efficacy and safety of the subcutaneous implantable cardioverter-defibrillator (S-ICD) compared with transvenous ICD (TV-ICD) and showed non-inferiority of the S-ICD with regard to the composite endpoint of device-related complications and inappropriate shocks (IAS) after 49.1 months. Complications associated with transvenous leads are expected to occur after longer follow-up. The PRAETORIAN-XL trial aims to investigate whether the S-ICD is superior to the TV-ICD with respect to device-related complications at 8-year follow-up. Methods: The PRAETORIAN trial randomized patients with a class I or IIa indication for ICD therapy without the need for pacing to either S-ICD or TV-ICD among 39 centers in the US and Europe between March 2011 and January 2017. The follow-up was extended after 49.1 months with an additional four years, for the PRAETORIAN-XL trial. The primary endpoint was the composite of all device-related complications. Complic

    Tweet Tweets with this article
    • #CircatHRS25 subcutaneous implantable cardioverter-defibrillator (S-ICD) is superior to the transvenous ICD (TV-ICD) w/ respect to device-related complications during long-term follow-up & should be considered in all patients w/o an indication of pacing. https://t.co/J8Axe5EWUu https://t.co/fieO5qej5f

  • Mashup Score: 7

    Background: There is sparse high-quality safety and effectiveness data for pulsed field ablation (PFA) of persistent atrial fibrillation (PerAF), where lesions beyond pulmonary vein isolation (PVI) are often placed. Additionally, no large trials have used insertable cardiac monitors (ICMs) for continuous rhythm monitoring post-ablation in PerAF patients, or after PFA in any AF population. In ADVANTAGE AF-Phase 2, PerAF patients underwent PFA for PVI and posterior wall ablation (PWA), and in a sub-cohort, cavotricuspid isthmus (CTI) ablation for typical atrial flutter. Methods: PerAF pts underwent PVI and PWA with the pentaspline PFA catheter, and CTI with a novel focal-linear PFA catheter after IV NTG prophylaxis. Patients were followed for 1 year with continuous rhythm monitoring after ablation with ICMs to 1) emulate traditional intermittent monitoring for the primary efficacy endpoint, and 2) examine atrial arrhythmia (AA) burden and episode duration. Results: This 255-patient cohor

    Tweet Tweets with this article
    • The ICM monitored Phase 2 of ADVANTAGE AF met safety and efficacy endpoints and supports the relationship of AF burden and HCU #CircatHRS25 @ed_gerst @atulverma_md @drjasonandrade @Drdevignair @AnishAminEP @ZiadIssaMD @VivekReddyMD https://t.co/1s1ymo5GXi